- Aspen Pharmacare Canada has received Health Canada approval for Aspen-Semaglutide, a generic equivalent of Ozempic (semaglutide injection), for adults with type 2 diabetes to improve glycemic control alongside diet and exercise.
- The product will be available in 2 mg and 4 mg pre-filled pen formats, offering once-weekly semaglutide dosing.
- Aspen is now preparing for the Canadian launch through pharmaceutical wholesalers, pharmacies, healthcare professionals, and other stakeholders. Commercialization timing will depend on the availability of semaglutide active pharmaceutical ingredient supply.
- The approval expands Aspen’s Canadian portfolio and could add another treatment option in the growing semaglutide market, as the company works toward broader patient access across the country.
Takeaways:
Aspen-Semaglutide’s approval introduces the generic Ozempic-equivalent into Canada’s GLP‑1 space, setting up price competition and broader access in type 2 diabetes once API supply constraints ease, and marking the start of semaglutide’s post‑patent phase where lower-cost weekly injectables from Aspen (and others) will pressure Novo Nordisk’s Ozempic/Wegovy franchise and help expand treatment uptake via wholesalers, pharmacies, and prescribers.
Source: CA Newswire
